
薬剤耐性に立ち向かう、抗菌薬イノベーションとシステム変革
抗菌薬を用いた治療は、現代医療の基盤として約1世紀にわたり、重要な役割を果たしてきました。ただし、この基盤は現在、薬剤耐性(AMR)によって脅かされています。AMRは急速にグローバル経済の喫緊の課題へ、そして公衆衛生の危機へと発展しています。
Cynderella Carlynda “Cyndy” Galimpin is an accomplished healthcare executive with long-standing leadership experience across Asia-Pacific. As Head of Animal Health for Boehringer Ingelheim’s Regional Operating Unit ASKAN, she leads cross-functional teams and business segments spanning ASEAN, South Korea, Australia and New Zealand, driving strategy and performance from her base in Singapore. She is also an Executive Committee Member of the Asian Animal Health Association.
Since joining Boehringer Ingelheim 18 years ago, Cyndy has held senior roles across Consumer Health Care and Human Pharma before transitioning to Animal Health. Her career includes serving as General Manager and Head of Human Pharma for Vietnam and earlier as President Director of Boehringer Ingelheim Indonesia. She is a vocal advocate for the One Health approach and vaccine-led prevention, partnering across public and private stakeholders to strengthen veterinary ecosystems and expand access - reflected in regional initiatives and thought leadership on antimicrobial resistance and sustainable growth in animal health.
抗菌薬を用いた治療は、現代医療の基盤として約1世紀にわたり、重要な役割を果たしてきました。ただし、この基盤は現在、薬剤耐性(AMR)によって脅かされています。AMRは急速にグローバル経済の喫緊の課題へ、そして公衆衛生の危機へと発展しています。
Antimicrobial resistance has grown beyond a simple health problem into an unprecedented threat to the stability of our health, economies and societies.
